Adverum Biotechnologies Inc (ADVM)
6.98
-0.27
(-3.72%)
USD |
NASDAQ |
Nov 15, 09:40
Adverum Biotechnologies Free Cash Flow (Quarterly): -21.34M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
Date | Value |
---|---|
September 30, 2024 | -21.34M |
June 30, 2024 | -19.86M |
March 31, 2024 | -23.34M |
December 31, 2023 | -21.52M |
September 30, 2023 | -24.41M |
June 30, 2023 | -23.28M |
March 31, 2023 | -22.50M |
December 31, 2022 | -18.66M |
September 30, 2022 | -32.63M |
June 30, 2022 | -35.31M |
March 31, 2022 | -33.30M |
December 31, 2021 | -30.17M |
September 30, 2021 | -31.52M |
June 30, 2021 | -37.56M |
March 31, 2021 | -23.71M |
December 31, 2020 | -23.66M |
September 30, 2020 | -29.63M |
June 30, 2020 | -20.02M |
March 31, 2020 | -17.83M |
December 31, 2019 | -23.21M |
September 30, 2019 | -15.72M |
June 30, 2019 | -14.08M |
March 31, 2019 | -15.40M |
December 31, 2018 | -12.89M |
Date | Value |
---|---|
September 30, 2018 | -17.17M |
June 30, 2018 | -11.52M |
March 31, 2018 | -13.20M |
December 31, 2017 | -12.30M |
September 30, 2017 | -10.17M |
June 30, 2017 | -11.89M |
March 31, 2017 | -12.08M |
December 31, 2016 | -9.266M |
September 30, 2016 | -10.01M |
June 30, 2016 | -9.228M |
March 31, 2016 | -12.28M |
December 31, 2015 | -9.314M |
September 30, 2015 | -10.54M |
June 30, 2015 | -10.32M |
March 31, 2015 | -8.153M |
December 31, 2014 | -5.419M |
September 30, 2014 | -5.078M |
June 30, 2014 | 5.30M |
March 31, 2014 | -1.394M |
December 31, 2013 | -0.73M |
September 30, 2013 | -0.591M |
June 30, 2013 | -0.723M |
March 31, 2013 | -0.222M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-37.56M
Minimum
Jun 2021
-17.83M
Maximum
Mar 2020
-25.67M
Average
-23.50M
Median
Free Cash Flow (Quarterly) Benchmarks
EyePoint Pharmaceuticals Inc | -40.60M |
Cassava Sciences Inc | -18.31M |
Regenxbio Inc | -40.88M |
Editas Medicine Inc | -55.51M |
Apellis Pharmaceuticals Inc | 34.10M |